Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases

Area of Science:

• Immunology
• Pharmacology
• Rheumatology

Background:

• Cytokines signal through the Janus kinase-Signal Transducers and Activators of Transcription (JAK-STAT) pathway, driving inflammatory and autoimmune diseases.
• Three JAK inhibitors (tofacitinib, baricitinib, ruxolitinib) are approved for conditions like rheumatoid arthritis and myeloproliferative neoplasms.

Purpose of the Study:

• To review the current status of approved and investigational JAK inhibitors.
• To discuss the rationale for developing selective JAK inhibitors for autoimmune and inflammatory diseases.

Main Methods:

• Narrative review of published literature.
• Analysis of approved JAK inhibitors and those in clinical trials.

Main Results:

• Approved JAK inhibitors target multiple JAKs with high potency.
• Numerous selective JAK inhibitors are in clinical development, indicating a shift towards targeted therapies.

Conclusions:

• Selective JAK inhibition offers a promising strategy for treating inflammatory and autoimmune diseases.
• Further research into selective JAK inhibitors is crucial for optimizing treatment outcomes.